NTBL Notable Labs Inc.: Market Capitalization to Book Value Ratio

Notable Labs, Ltd. (NTBL) combines AI-driven live-cell screening with an express biosample delivery system, creating a B2B partnership with pharma behemoths. The market cap to book value ratio on GURU.Markets visualizes this synergy, where the current parameter equals 0.33. However, success depends on the platform's implementation in clinics and strict control of R&D expenses amid limited capital reserves.

Notable Labs, Ltd. (NTBL) - Market Capitalization to Book Value Ratio from 02/21/2024 to 11/02/2024

NTBL (Notable Labs Ltd): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Notable Labs, Ltd.|NTBL - Price Target Chart
- market capitalization data:
Market Capitalization Notable Labs Inc.|NTBL - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Notable Labs|NTBL - Book Capitalization|Market Value to Book Value Ratio notablelabs.com|NTBL - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Notable Labs, Ltd.|NTBL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Notable Labs Inc.|NTBL - Company Cumulative Debt|Debt to Book Capitalization Ratio Notable Labs Inc.|NTBL - Company Long-Term Loans and Borrowings|Company Current Liabilities Notable Labs
Fundamental valuation:NTBL (Notable Labs, Ltd.)

Notable Labs, Ltd. (NTBL) is developing an AI platform for the personalization of oncology therapies, leveraging venture capital. This price-to-book ratio reflects the premium or discount of the business value relative to its net assets. The metric is calculated by dividing the current market capitalization by the equity. A decline in this indicator below industry averages signals a "value trap" risk. For a startup, this serves as a tool to balance speculative optimism against the actual value of its resources.

Main competitors

BeiGene Ltd (ONC) - Market Value to Book Value Ratio|halozyme.com (HALO) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio RVMD|Market Cap to Net Assets Ratio Ascentage Pharma Group International|Market Capitalization to Book Value Ratio CGON|Market Capitalization to Book Value Ratio URGN (UroGen Pharma Corp)|BCAX - Market Value to Book Value Ratio|Capitalization to Book Value Ratio personalis.com PSNL|ERAS: Market Capitalization to Book Value Ratio|DCTH - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio YMAB|AURA (Aura Corp) - Market-to-Book Ratio|CADL - Market Value to Book Value Ratio|Market Value to Book Value accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Market Cap to Net Assets Ratio|Market Value to Book Value Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Market Capitalization to Book Value Ratio|HURA - Market Cap to Net Assets Ratio|Protara Therapeutics - Market Cap to Net Assets Ratio|FATE: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio CSBR (Champions Oncology Inc)|Market-to-Book Ratio XBIT|Market Value to Book Value Ratio CEL-SCI Corporation CVM|Capitalization to Book Value Ratio OSTX (ostherapies.com)|RADX: Market Value to Book Value Ratio|ARTV - Market-to-Book Ratio|Market Cap to Net Assets Ratio Adlai Nortye Limited ANL|VERU - Market Cap to Book Value Multiple|TPST: Market Capitalization to Book Value Ratio|Xilio Therapeutics (XLO) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Renovaro Biosciences|Market Value to Book Value Ratio MURA|Market Value to Book Value Ratio Kairos Pharma Ltd (KAPA)|Market Value to Book Value Ratio onkuretherapeutics.com (OKUR)|GDTC: Market Capitalization to Book Value Ratio|CRIS - Market-to-Book Ratio|Market Cap to Net Assets Ratio Apollomics Corp (APLM)|THAR: Market Value to Book Value|advanbiomed.com (ADVB) - Market Value to Book Value Ratio|Genprex Inc (GNPX) - Market Value to Book Value Ratio|CLDI (Calidi Biotherapeutics Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio sunshinebiopharma.com|Market Capitalization to Book Value Ratio Xenetic Biosciences (XBIO)|Market Value to Book Value Ratio SLRX (Salarius Pharmaceuticals Inc)|Market Value to Book Value Ratio PPBT|AONC - Market Capitalization to Book Value|Market Cap to Net Assets Ratio BeiGene, Ltd. (BGNE)|CKPT: Market Value to Book Value|Elevation Oncology (ELEV) - Market Value to Book Value Ratio|Market Value to Book Value Ratio iCAD|Ikena Oncology Inc. (IKNA) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple Viracta|Market Capitalization to Book Value Ratio MorphoSys AG MOR|Capitalization to Book Value Ratio nayabiosciences.com NAYA|Market Cap to Net Assets Ratio AAPGV